Pharma Giants Reshape Portfolios as Oncology Pipelines Drive Sector Optimism
Major pharmaceutical companies are simultaneously advancing oncology pipelines and restructuring corporate operations, creating a complex but bullish backdrop for sector investors. Johnson & Johnson's acquisition spree, Roche's updated financial outlook, and Pfizer's FDA priority review for HYMPAVZI signal active portfolio optimization. Mid-tier player Orion projects 2026 revenues of €1.9–2.1 billion as R&D investment accelerates.
ViaNews Editorial Team (Markets)•